Positive regulatory milestones de-risk QRX003 and support potential NDA filing in 2027. Monitor Phase 3 patient recruitment completion by end of 2026 for next catalyst. Dilution risk from ADS issuance warrants caution given low market cap.
Price Chart
Executive Summary
Quoin Pharmaceuticals reported Q1 2026 loss per ADS of $(1.77), beating consensus of $(2.26), with no revenue. The company highlighted significant regulatory progress for QRX003 in Netherton Syndrome, including FDA Fast Track designation and a constructive Type C meeting suggesting a single Phase 3 study may suffice for approval. Cash balance of $14M is expected to fund operations into 2027.
Key Financial Metrics
Key Facts
- Q1 2026 loss per ADS $(1.77) vs consensus $(2.26), beat of 21.7%
- No revenue reported; net loss widened to $5.0M from $3.8M YoY
- FDA granted Fast Track Designation for QRX003 (Netherton Syndrome)
- FDA indicated a single Phase 3 study may be sufficient for marketing approval
- Cash and investments $14M as of March 31, 2026, providing runway into 2027
Financial Impact
Pre-revenue biotech; cash burn increased to $5M per quarter, but cash position adequate into 2027
Risk Factors
- Dilution from ADS issuances (outstanding ADS increased 2.8x YoY)
- Clinical trial failure or delay
- Cash runway limited; may require additional financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290007 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 6d ago | ANALYST-UPGRADE | $4.36 $4.15 | ▼ −4.82% | ▼ −4.80% | $3.90 (−10.55%) |
Sep 2, 2026 6w ago | Insider Cluster | $6.74 $7.87 | ▲ +16.77% | ▲ +15.72% | $3.90 (−42.14%) |
Aug 28, 2026 7w ago | 8-K | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▼ −1.63% | ▼ −1.93% | $3.90 (+36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 20, 2026 8w ago | 8-K | $5.57 $5.42 | ▼ −2.69% | ▼ −2.40% | $3.90 (−29.98%) |
Aug 7, 2026 10w ago | Press Release | $4.79 $5.36 | ▲ +11.90% | ▲ +11.93% | $3.90 (−18.58%) |
Jun 23, 2026 16w ago | 8-K | $3.83 $4.20 | ▲ +9.66% | ▲ +9.52% | $3.90 (+1.83%) |
May 7, 2026 23w ago | Press Release | $6.37 $5.93 | ▼ −6.91% | ▼ −7.74% | $3.90 (−38.78%) |
May 5, 2026 23w ago | ANALYST-UPGRADE | $6.31 $6.43 | ▲ +1.90% | ▲ +0.52% | $3.90 (−38.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access